We further examined the effect of FTI treatment using lonafarnib in a clinically relevant setting with a patient-derived xenograft (PDX) model from a prostate cancer metastatic lesion harboring the SPOP F133L mutation and AR expression (Supplemental Figure 7G). Here, SPOP is linked to Familial prostate cancer.